Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment
Regulatory Filings Classification · 89% confidence The document is a corporate press release announcing the company’s intention to file a regulatory application (Type II variation) with the European Medicines Agency and providing investor webcast details. It does not contain actual financial statements or transaction details, nor is it a meeting agenda or voting result. It is a general regulatory announcement required under EU Market Abuse Regulation rather than an earnings, financial report, or proxy document. Therefore, it best fits the fallback category for general regulatory filings.
2026-05-11 English
Oncopeptides avser lämna in en typ II-variation för att expandera Pepaxtis indikation till behandling i tredje linjen
Regulatory Filings Classification · 72% confidence The document is a press release disclosing the company’s intention to file a Type II variation with the EMA to expand a drug indication and invites investors to a webcast. It contains no financial statements, no earnings data, no management or governance materials, and is not the actual regulatory report itself but a regulatory announcement under EU Market Abuse rules. It does not fit other specific categories and thus falls under the general regulatory announcement/fallback category.
2026-05-11 Swedish
Annual Report (ESEF) 2025
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-04-28 Swedish
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 92% confidence The document is a Swedish Financial Supervisory Authority (Finansinspektionen) “flaggningsmeddelande” showing a third‐party investor (Avanza Bank Holding AB via its subsidiary) crossing the 5% ownership threshold in Oncopeptides AB, with detailed pre‐ and post‐transaction share counts and percentages. This is a Major Shareholding Notification under takeover/market disclosure rules, matching our Major Shareholding Notification (MRQ) category.
2026-04-24 Swedish
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a "flaggningsmeddelande" published by the Swedish Financial Supervisory Authority (Finansinspektionen) detailing a purchase that crosses the 5% voting rights threshold for Oncopeptides AB. It contains specific share counts before and after the transaction and references LHF (Swedish flagging law) requirements. This matches the definition of a Major Shareholding Notification (Code: MRQ).
2026-04-21 Swedish
Årsstämma i Oncopeptides
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a Swedish press release calling shareholders to the 2026 Annual General Meeting of Oncopeptides AB. It provides detailed instructions for registration, participation (in person or by pre-voting), the full agenda, and the board’s proposals on resolutions to be voted on. This is not the annual report itself nor an earnings release or a simple announcement of publication; rather, it is information and materials sent to shareholders to solicit votes at the meeting. Therefore, it best fits the Proxy Solicitation & Information Statement category.
2026-04-16 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.